I just dug this one up from the pile.

BET inhibitors act synergistically with PARP inhibitors

Also, I found one of Fouremm's posts that noted some talk about Zentith and PARP as the Sept AGM:

"I just listened to the presentation again. As well as mentioning PARP inhibitors at slide 7, Don lists 3 publications on slide 23 that suggest “a PARP inhibitor and a BET inhibitor are going to have a major impact in triple -ve breast cancer”. This is where Zenith will be starting wrt breast cancer in combo with a PARP inhibitor."

Slide 23 can be found here.